Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

Kasiske, Bertram L.; O’Donnell, Michael P.; Cleary, Margot P.; Keane, William F.

doi:10.1038/ki.1988.51

Cited by 415 publications

(191 citation statements)

References 19 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…During the second 6 weeks the patients received a placebo (twice a day) and information collected during this period served as baseline data. Then the patients were randomly assigned to a 6 weeks' treatment period with simvastatin 20 mg twice a day or cholestyramine 8 …”

Section: Study Design and Laboratory Methodsmentioning

confidence: 99%

Effects of Simvastatin and Cholestyramine on Lipoprotein Profile in Hyperlipidaemia of Nephrotic Syndrome

Rabelink¹,

Erkelens²,

Hené³

et al. 1988

The Lancet

View full text Add to dashboard Cite

show abstract

Section: Study Design and Laboratory Methodsmentioning

confidence: 99%

Effects of Simvastatin and Cholestyramine on Lipoprotein Profile in Hyperlipidaemia of Nephrotic Syndrome

Rabelink¹,

Erkelens²,

Hené³

et al. 1988

The Lancet

View full text Add to dashboard Cite

show abstract

“…Hyperlipidaemia has been shown to play a role in initiation and progression of glomerular injury in animal models [38,39]. A positive correlation has been found between serum cholesterol and rate of decline in glomerular filtration rate in IDDM patients with diabetic nephropathy [17] and in proteinuric non-diabetic patients [24].…”

Section: Discussionmentioning

confidence: 99%

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

et al. 1994

View full text Add to dashboard Cite

Summmr/ Diabetic nephropathy is the main cause of increased mortality and morbidity in IDDM patients. The effect of antihypertensive treatment on the progression of the nephropathy is highly variable. The aim of this study was to evaluate putative predictors of the progression in diabetic nephropathy during long-term antihypertensive treatment. Eighteen hypertensive IDDM patients with diabetic nephropathy, who had not been treated previously, were followed during 3 years of treatment with captopril and frusemide or bendrofluazide. Glomerular filtration rate, arterial blood pressure, albuminuria and adjusted albuminuria were used as putative predictors of rate of decline in glomerular filtration. Fall rate in glomerular filtration rate was 4.6 (4.0) ml. min-1 .year 1 (mean (SD)) during treatment. Relative change in albuminuria (ratio of first year of treatment/baseline) and albuminuria during first year of treatment were significantly correlated to fall rate in glomerular filtration rate during 3 years of treatment (r --0.73, p < 0.001) and (r = 0.60, p < 0.01), respectively. Arterial blood pressure and glomerular filtration rate measured at baseline, during first year of treatment or relative changes in these variables did not correlate with fall rate in glomerular filtration rate during 3 years of treatment. Haemoglobin AI:, serum-cholesterol, protein intake and sodium excretion remained unchanged during treatment, and were not correlated with loss of kidney function. Reduction in albuminuria during captopril treatment predicts an attenuated rate of decline in glomerular filtration rate in early diabetic nephropathy (glomerular filtration rate > 70 ml. rain -1-1.73 m-Z). The finding suggests a clinical application in monitoring the efficacy of antihypertensive treatment in early diabetic nephropathy. [Diabetologia (1994) 37: 511-516] Key words Diabetic nephropathy, albuminuria, antihypertensive treatment, glomerular filtration rate.Diabetic nephropathy develops in 30-40 % of IDDM patients [1,2], and nephropathy is the main cause of increased morbidity and mortality in these patients [1]. Diabetic nephropathy is a clinical syndrome characterized by persistent albuminuria, a relentless decline in glomerular filtration rate, and raised arterial blood pressure [3]. Human and animal studies have demonstrated a correlation between elevation in arterial Received: 21 September 1993 and in revised form: 3 December 1993Corresponding author: Dr. R Rossing~ Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, DenmarkAbbreviations: IDDM, Insulin-dependent diabetes mellitus blood pressure and development and progression of diabetic glomerulopathy [4][5][6][7][8][9][10]. Several studies [11][12][13][14][15][16][17] have demonstrated that the rate of decline in glomerular filtration rate can be reduced by antihypertensive treatment. However the beneficial effect of antihypertensive treatment on the progression of the diabetic nephropathy is highly variable. From a clinical point of view, identification of predic...

show abstract

“…Animal studies have shown development and progression of kidney damage in the setting of hyperlipidemia with increased glomerulosclerosis and tubulointerstitial damage (3)(4)(5)(6). In epidemiologic studies, the presence of dyslipidemia was associated with a higher risk of development of incident CKD in the general population (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Relation of Serum Lipids and Lipoproteins with Progression of CKD

Rahman

Yang

Akkina

et al. 2014

Clinical Journal of the American Society of Nephrology

148

View full text Add to dashboard Cite

Background and objectives Hyperlipidemia is common in patients with CKD. The objective of this study was to evaluate whether measures of plasma lipids and lipoproteins predict progression of kidney disease in patients with CKD.Design, setting, participants, & measurements Prospective cohort study in adults (n=3939) with CKD aged 21-74 years recruited between 2003 and 2008 and followed for a median of 4.1 years. At baseline, total cholesterol, triglycerides, very-low-density lipoprotein cholesterol (VLDL-C), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), apoA-I , apoB, and lipoprotein(a) [Lp(a)] were measured. The outcomes were composite end point of ESRD or 50% decline in eGFR from baseline (rate of change of GFR).Results Mean age of the study population was 58.2 years, and the mean GFR was 44.9 ml/min per 1.73 m 2 ; 48% of patients had diabetes. None of the lipid or lipoprotein measures was independently associated with risk of the composite end point or rate of change in GFR. However, there were significant (P=0.01) interactions by level of proteinuria. In participants with proteinuria,0.2 g/d, 1-SD higher LDL-C was associated with a 26% lower risk of the renal end point (hazard ratio [HR], 0.74; 95% confidence interval [95% CI], 0.59 to 0.92; P=0.01), and 1-SD higher total cholesterol was associated with a 23% lower risk of the renal end point (HR, 0.77; 95% CI, 0.62 to 0.96; P=0.02). In participants with proteinuria.0.2 g/d, neither LDL-C (HR, 0.98; 95% CI, 0.98 to 1.05) nor total cholesterol levels were associated with renal outcomes. Treatment with statins was reported in 55% of patients and was differential across lipid categories.Conclusions In this large cohort of patients with CKD, total cholesterol, triglycerides, VLDL-C, LDL-C, HDL-C, apoA-I, apoB, and Lp(a) were not independently associated with progression of kidney disease. There was an inverse relationship between LDL-C and total cholesterol levels and kidney disease outcomes in patients with low levels of proteinuria.

show abstract

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

Cited by 415 publications

References 19 publications

Effects of Simvastatin and Cholestyramine on Lipoprotein Profile in Hyperlipidaemia of Nephrotic Syndrome

Effects of Simvastatin and Cholestyramine on Lipoprotein Profile in Hyperlipidaemia of Nephrotic Syndrome

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

Relation of Serum Lipids and Lipoproteins with Progression of CKD

Contact Info

Product

Resources

About